CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenues:
Net product sales	$ 924,133	$ 834,219	$ 1,782,378	$ 1,618,401
Sanofi collaboration revenue	222,128	163,414	432,495	383,108
Bayer Collaboration Revenue	210,355	191,896	404,294	371,488
Other revenue	113,500	23,100	169,940	40,481
Total revenues	1,470,116	1,212,629	2,789,107	2,413,478
Expenses:
Research and development	509,975	559,930	1,017,410	1,030,042
Selling, general, and administrative	306,908	292,038	603,754	581,715
Cost of goods sold	42,133	41,247	103,386	120,189
Cost of collaboration and contract manufacturing	60,788	27,786	83,703	60,596
Total expenses	919,804	921,001	1,808,253	1,792,542
Income from operations	550,312	291,628	980,854	620,936
Other income (expense):
Other income (expense), net	(19,061)	1,879	(9,813)	5,362
Interest expense, net	(5,401)	(1,251)	(12,902)	(3,891)
Total other income (expense)	(24,462)	628	(22,715)	1,471
Income before income taxes	525,850	292,256	958,139	622,407
Income tax expense	(138,106)	(96,038)	(321,464)	(244,804)
Net income	$ 387,744	$ 196,218	$ 636,675	$ 377,603
Net income per share - basic	$ 3.66	$ 1.88	$ 6.02	$ 3.61
Net income per share - diluted	$ 3.34	$ 1.69	$ 5.51	$ 3.24
Weighted average shares outstanding - basic	106,034	104,633	105,804	104,462
Weighted average shares outstanding - diluted	116,137	116,231	115,607	116,617
Statements of Comprehensive Income
Net income	$ 387,744	$ 196,218	$ 636,675	$ 377,603
Other comprehensive income (loss), net of tax:
Unrealized gain (loss) on marketable securities	8,204	840	15,160	(3,368)
Unrealized gain on cash flow hedges	28	0	28	0
Comprehensive income	$ 395,976	$ 197,058	$ 651,863	$ 374,235